MB0151
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MB0151, covering 2025-12-02 to 2025-12-02. Get the full timeline:
Most recent: Clinical Trial Update: Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors [Phase 1, Phase 2]